Plexiform-like lesions and increased tissue factor expression in a rat model of severe pulmonary arterial hypertension.

  title={Plexiform-like lesions and increased tissue factor expression in a rat model of severe pulmonary arterial hypertension.},
  author={R. James White and David F. Meoli and Robert F. Swarthout and Dara Y. Kallop and Irfan I. Galaria and Jennifer L. Harvey and Christine M. Miller and Burns C. Blaxall and C M Hall and Richard A. Pierce and Carlyne D Cool and Mark B. Taubman},
  journal={American journal of physiology. Lung cellular and molecular physiology},
  volume={293 3},
  • R. WhiteD. Meoli M. Taubman
  • Published 1 September 2007
  • Biology, Medicine
  • American journal of physiology. Lung cellular and molecular physiology
Severe pulmonary arterial hypertension (PAH) occurs in idiopathic form and in association with diverse diseases. The pathological hallmarks are distal smooth muscle hypertrophy, obliteration of small pulmonary arteriole lumens, and disorganized cellular proliferation in plexiform lesions. In situ thrombosis is also observed. A detailed understanding of the disease progression has been hampered by the absence of an animal model bearing all the pathological features of human disease. To create a… 

Figures and Tables from this paper

Formation of Plexiform Lesions in Experimental Severe Pulmonary Arterial Hypertension

Severe, sustained pulmonary hypertension in a very late stage of the Sugen 5416/hypoxia/normoxia-exposed rat is accompanied by the formation of lesions that are indistinguishable from the pulmonary arteriopathy of human pulmonary arterial hypertension.

Development and Characterization of an Animal Model of Severe Pulmonary Arterial Hypertension

The present data indicate that a combined treatment of monocrotaline injection and hypobaric chronic hypoxia exposure produces more severe hemodynamic changes and histological alterations.

The role of disturbed blood flow in the development of pulmonary arterial hypertension: lessons from preclinical animal models.

The current knowledge obtained from PAH animal models associated with disturbed pulmonary blood flow is summarized, questions for future treatment strategies for PAH are addressed and a review that underlines the current knowledge of PAH due to disturbed flow is still lacking is needed.

Reversible or irreversible remodeling in pulmonary arterial hypertension.

The pathogenetic concepts of severe PAH are reviewed and it is suggested that the proliferative state of SMC may be reversible, it remains unknown whether phenotypically altered EC can switch back to a normal monolayer-forming EC.

REVIEW Plexiform Arteriopathy in Rodent Models of Pulmonary Arterial Hypertension

P38 mitogen-activated protein kinase activation emerges as a central molecular mediator of plexiform lesions in both experimental models and human disease, and this review will focus on plexodus arteriopathy in experimental animal models of PAH.

Chronic hypoxia aggravates monocrotaline-induced pulmonary arterial hypertension: a rodent relevant model to the human severe form of the disease

A rat model of severe PAH generated by combining a single injection of monocrotaline with 4 weeks exposure to chronic hypoxia is characterized, with severe pulmonary arteriopathy observed, with thrombotic, neointimal and plexiform-like lesions similar to those observed in human severePAH.

Rodent models of group 1 pulmonary hypertension.

This review assesses the fidelity of existing animal models to human PAH and concludes that Murine models offer greater molecular certainty than rat models but rarely develop significant PH, have less right ventricular hypertrophy (RVH) and pulmonary artery (PA) remodeling, and are harder to image and catheterize.

Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure.

This review highlights progress that has been made in animal modeling of this important human condition and uses both classic and newly developed animal models to allow continued rigorous testing of new hypotheses regarding pathogenesis and treatment.

Pulmonary hypertension: the science behind the disease spectrum

  • M. Wilkins
  • Biology, Medicine
    European Respiratory Review
  • 2012
Further research is required to unravel and integrate the molecular changes into a better understanding of the pathophysiology of PH, particularly in non-PAH, to put us in a better position to use this knowledge for improved treatments.



Development of Occlusive Neointimal Lesions in Distal Pulmonary Arteries of Endothelin B Receptor—Deficient Rats: A New Model of Severe Pulmonary Arterial Hypertension

It is shown that exposure of ETB receptor–deficient rats to the endothelial toxin monocrotaline (MCT) leads to the development of neointimal lesions that share hallmarks of human PAH, and an overall antiproliferative effect of the ETB receptors in pulmonary vascular homeostasis is suggested.

Expression of angiogenesis‐related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis

It is postulated that in lungs with SPH, endothelial cells in plexiform lesions express genes encoding for proteins involved in angiogenesis, in particular, vascular endothelial growth factor (VEGF) and those involved in VEGF receptor‐2 (VEGFR‐2) signalling.

Reversal of experimental pulmonary hypertension by PDGF inhibition.

STI571 reverses vascular remodeling and cor pulmonale in severe experimental pulmonary hypertension regardless of the initiating stimulus, and offers a unique novel approach for antire-modeling therapy in progressed pulmonary hypertension.

Pulmonary arterial hypertension

Pulmonary arterial hypertension is a disease of the small pulmonary arteries characterized by vascular narrowing and increased pulmonary vascular resistance, which eventually leads to right

Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry.

The present study shows the existence of several distinct histopathologic patterns of pulmonary vascular disease in individuals with primary pulmonary hypertension diagnosed by standardized clinical and laboratory criteria.

Simvastatin Rescues Rats From Fatal Pulmonary Hypertension by Inducing Apoptosis of Neointimal Smooth Muscle Cells

Simvastatin reverses pulmonary arterial neointimal formation and PAH after toxic injury and downregulated the inflammatory genes fos, jun, and tumor necrosis factor-&agr; and upregulated the cell cycle inhibitor p27Kip1, endothelial nitric oxide synthase, and bone morphogenetic protein receptor type 1a.

Mice deficient in tissue factor demonstrate attenuated intimal hyperplasia in response to vascular injury and decreased smooth muscle cell migration

The data suggest that TF may mediate intimal hyperplasia by regulating smooth muscle cell migration by regulating non-procoagulant properties of TF.

Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death‐dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension

It is demonstrated here that VEGFR‐2 blockade with SU5416 in combination with chronic hypobaric hypoxia causes severe pulmonary hypertension associated with precapillary arterial occlusion by proliferating endothelial cells.